Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project
2008

IgA Antibodies in Early Rheumatoid Arthritis

Sample size: 228 publication Evidence: moderate

Author Information

Author(s): Anna Svärd, Alf Kastbom, Åsa Reckner-Olsson, Thomas Skogh

Primary Institution: Rheumatology Clinic, Falu Hospital, Sweden

Hypothesis

Do IgA-class antibodies against cyclic citrullinated peptides provide additional diagnostic or prognostic information in early rheumatoid arthritis?

Conclusion

IgA anti-CCP antibodies are present in about one-third of early rheumatoid arthritis patients and are associated with a more severe disease course, but do not add diagnostic value beyond IgG anti-CCP analysis.

Supporting Evidence

  • 29% of patients tested positive for IgA anti-CCP.
  • IgA anti-CCP-positive patients had higher disease activity over time.
  • The presence of IgA anti-CCP was significantly associated with smoking.

Takeaway

This study found that some people with early rheumatoid arthritis have a type of antibody that could mean their disease is worse, but it doesn't help doctors diagnose the disease better than another type of antibody.

Methodology

Serum samples were collected from 228 patients with recent-onset rheumatoid arthritis, and disease activity was measured over 3 years.

Potential Biases

The treating physicians were unaware of the patients' antibody statuses, which may reduce bias.

Limitations

The study did not include radiographic follow-up and relied on self-reported smoking status.

Participant Demographics

The study included 228 patients, with a mean age of 55 years, and a gender distribution of 158 women and 70 men.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar2449

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication